Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritis.
Lo Gullo A, Parisi S, Becciolini A, Paroli M, Bravi E, Andracco R, Nucera V, Ometto F, Lumetti F, Farina A, Del Medico P, Colina M, Ravagnani V, Scolieri P, Larosa M, Priora M, Visalli E, Addimanda O, Vitetta R, Volpe A, Bezzi A, Girelli F, Molica Colella AB, Caccavale R, DI Donato E, Adorni G, Santilli D, Lucchini G, Arrigoni E, Platè I, Mansueto N, Ianniello A, Fusaro E, Ditto MC, Bruzzese V, Camellino D, Bianchi G, Serale F, Foti R, Amato G, DE Lucia F, Dal Bosco Y, Foti R, Reta M, Fiorenza A, Rovera G, Marchetta A, Focherini MC, Mascella F, Bernardi S, Sandri G, Giuggioli D, Salvarani C, DE Andres MI, Franchina V, Molica Colella F, Ferrero G, Ariani A. Lo Gullo A, et al. Among authors: becciolini a. Minerva Med. 2024 Aug;115(4):430-438. doi: 10.23736/S0026-4806.24.09409-6. Minerva Med. 2024. PMID: 39376099
Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Benucci M, Gobbi FL, Guiducci S, Foti R, Mosca M, Goletti D. Cantini F, et al. Among authors: becciolini a. Semin Arthritis Rheum. 2017 Oct;47(2):183-192. doi: 10.1016/j.semarthrit.2017.03.008. Epub 2017 Mar 22. Semin Arthritis Rheum. 2017. PMID: 28413099 Review.
Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG, Sinigaglia L, Becciolini A, Grosso V, Gorla R, Bazzani C, Atzeni F, Sarzi Puttini PC, Fusaro E, Pellerito R, Caporali R. Favalli EG, et al. Among authors: becciolini a. Int J Rheum Dis. 2018 Feb;21(2):422-430. doi: 10.1111/1756-185X.13199. Epub 2017 Oct 30. Int J Rheum Dis. 2018. PMID: 29082659
Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
Favalli EG, Becciolini A, Carletto A, Conti F, Amato G, Fusaro E, Quartuccio L, Egan CG, Lo Monaco A, Benucci M, Salaffi F, Semeraro A, Parisi S, Ceccarelli F, Piazza I, Foti R. Favalli EG, et al. Among authors: becciolini a. Rheumatol Int. 2020 Feb;40(2):263-272. doi: 10.1007/s00296-019-04416-3. Epub 2019 Aug 21. Rheumatol Int. 2020. PMID: 31435754
bDMARDs retention rate in the biosimilar era: A real-life monocentric study.
Becciolini A, Lumetti F, Donato ED, Giordano S, Santilli D, Mozzani F, Riva M, Lucchini G, Ariani A. Becciolini A, et al. Eur J Rheumatol. 2021 Apr;8(2):109-110. doi: 10.5152/eurjrheum.2020.20080. Eur J Rheumatol. 2021. PMID: 32910769 Free PMC article. No abstract available.
152 results